Abstract:In the past ten years we have made exceptional progresses in the understanding of RCC biology, particularly by recognizing the crucial pathogenetic role of activation of the HIF/VEGF and mTOR pathways. This has resulted in the successful clinical development of anti-angiogenic and mTOR-targeted drugs, which have profoundly impacted on the natural history of the disease and have improved the duration and quality of RCC patient lives. However, further improvements are still greatly needed: 1) even in patients who obtain striking clinical responses early in the course of treatment, disease will ultimately escape control and progress to a treatment-resistant state, leading to therapeutic failure; 2) prolonged disease control usually requires 'continuous' treatment, even across different treatment lines, making the impact of chronic, low-grade, toxicities on quality of life greater and precluding, for most patients, the possibility of experiencing 'drug-free holidays'; 3) although we have successfully identified classes of drugs (or molecular mechanisms of action) that are effective in a substantial proportion of patients, we still fall short of molecular predictive factors that identify individual patients who will (or will not) benefit from a specific intervention and still proceed on a trial-and-error basis, far from a truly 'personalized' therapeutic approach; 4) finally (and perhaps most importantly), even in the best case scenario, currently available treatments inevitably fail to definitively 'cure' metastatic RCC patients. In this review we briefly summarize recent developments in the understanding of the molecular pathogenesis of RCC, the development of resistance/escape mechanisms, the rationale for sequencing agents with different mechanisms of action, and the importance of host-related factors. Unraveling the complex mechanisms by which RCC shapes host microenvironment and immune response and therapeutic treatments, in turn, shape both cancer cell biology and tumor-host interactions may hold the key to future advances in such a complex and challenging disease.

Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review

Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review

Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Local Therapy for Metastatic Colorectal Cancer: A Case-Based Review

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review

Biology of metastatic renal cell carcinoma

Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy

Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

Local Therapy for Metastatic Colorectal Cancer

Targeted therapy of metastatic renal cell carcinoma

A narrative review of the evolving landscape of the management of metastatic gastric cancer: the role of targeted therapies

Multidisciplinary approach of liver metastases from colorectal cancer

New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives

Metastasis-directed therapy in testicular cancer

Systemic therapy for non–clear cell renal cell carcinomas: A systematic review

Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review

Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era

Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Advances in immunotherapy of metastatic renal cell carcinoma